AS 1409

Drug Profile

AS 1409

Alternative Names: Antibody-cytokine fusion drug (AS1409); AS-1409; BC1-IL-12; hBC1-hIL-12; huBC1/IL-12 fusion protein; huBC1/IL12 fusion drug; Tumour-targeting antibody BC1/IL-12 fusion drug

Latest Information Update: 19 Jul 2012

Price : $50

At a glance

  • Originator Antisoma; EMD Lexigen
  • Developer Antisoma
  • Class Antibodies; Antineoplastics; Cytokines; Interleukins; Monoclonal antibodies
  • Mechanism of Action Interferon gamma stimulants; Natural killer cell stimulants; Th1 cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Malignant melanoma; Renal cancer

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 11 Jan 2012 Discontinued - Phase-I for Malignant melanoma in New Zealand (IV)
  • 11 Jan 2012 Discontinued - Phase-I for Malignant melanoma in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top